Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255151 · ClinicalTrials.gov registry record · Phase 3
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
A Phase 3 study of Esophagitis, Reflux and Esophagitis, Peptic, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 451
- Enrollment target
- 20
- Study locations
NCT00255151 is a Phase 3 study of Esophagitis, Reflux and Esophagitis, Peptic that has completed, run by Takeda. The registered enrollment target is 451 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT00255151, a Phase 3 study of Esophagitis, Reflux and Esophagitis, Peptic, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 451 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dexlansoprazole MR
Study Locations (20)
California
- - Azusa
- - Carmichael
- - Cypress
- - Fresno
- - Los Angeles
- - Modesto
- - Newport Beach
- - Oakland
- - Orange
- - San Diego
- - Santa Maria
Alabama
- - Anniston
- - Hueytown
- - Huntsville
- - Tallassee
- - Tuscaloosa
Arkansas
- - Little Rock
- - North Little Rock
Arizona
- - Tucson
Colorado
- - Littleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 451 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255151
The ClinicalTrials.gov registry entry for NCT00255151 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 451 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Esophagitis, Reflux appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00255151 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00255151 about?
NCT00255151 is a clinical study titled "Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis". The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
What is the current status of trial NCT00255151?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 451 participants. The study started on 2006-01. Estimated completion is 2006-11.
What conditions does trial NCT00255151 study?
This clinical trial studies the following conditions: Esophagitis, Reflux, Esophagitis, Peptic.
What interventions are being tested in trial NCT00255151?
The interventions under investigation include: Placebo (DRUG), Dexlansoprazole MR (DRUG).
Who is sponsoring clinical trial NCT00255151?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00255151 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophagitis, Reflux
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.